ERBB2 and breast cancer: Using the median H-score of 30 as threshold, TweakR was considered as positive in 12/31 ERBB2 positive carcinomas (39%), 14/39 basal-like tumors (36%), 12/28 luminal A tumors (43%), and 22/36 luminal B tumors (61%), with an overall positive expression in 45% of all tested samples of breast cancer.